Plasmacytoma
The content provided herein is for informational and educational purposes only. it does not constitute an endorsement or promotion of any specific diagnostic methods, treatments, or pharmaceutical products. This information is not a substitute for professional medical advice, diagnosis, or treatment from a qualified physician or pharmacist. It should not be used as a basis for self-diagnosis or for starting, modifying, or discontinuing any medical treatment. Always seek the advice of your physician or another qualified healthcare provider with any questions you may have regarding a medical condition or health concerns.
Plasmacytoma is often described as a form of bone marrow cancer. It is a disease of plasma cells in the bone marrow (plasma cell disorder). These cells multiply in one limited area.
A plasmacytoma can occur in bone. This is called a solitary plasmacytoma of bone. It can also occur outside the bone in soft tissue. This is called an extramedullary plasmacytoma. It is also important to distinguish it from multiple myeloma. Both diseases are cancers of B lymphocytes, more precisely plasma cells. Unlike multiple myeloma, plasmacytoma is usually localised at first. It does not affect the entire bone marrow at this stage. However, plasmacytoma can later develop into multiple myeloma. Careful diagnosis and follow-up are therefore especially important.
Prof. Dr. med. Dipl.-Med. Holger Wehner
Plasmacytoma requires careful diagnosis and long-term monitoring. Complementary approaches such as hyperthermia may help support the body and enhance quality of life throughout treatment.
Plasmacytoma causes and risk factors
The exact causes of plasmacytoma are not fully clear. This is similar to multiple myeloma. The disease usually cannot be traced back to one single clear factor. It starts when plasma cells change abnormally. Plasma cells are mature B lymphocytes that normally produce antibodies. In plasmacytoma, this abnormal cell growth stays localised at first. It can occur in bone or in soft tissue.
Some risk factors are described in connection with plasmacytoma. These include:
- Older age
- Male sex
- Precursors of plasma cell disorders
- A family history of plasma cell disorders or multiple myeloma
- Ethnic background, especially African ancestry
- Environmental and exposure factors, such as ionising radiation, pesticides or organic solvents
It is important to stress again that plasmacytoma usually does not have one single cause. Experts describe biological and epidemiological risk patterns that may make the disease more likely. This is why careful diagnosis is so important. Doctors need to distinguish a local plasmacytoma from systemic multiple myeloma. This distinction affects treatment, follow-up and prognosis.
Plasmacytoma symptoms
Plasmacytoma symptoms vary. They depend on the location and on how far the surrounding tissue is affected. Since plasmacytoma is localised at first, symptoms are often local too. In contrast, multiple myeloma often causes systemic effects. These can include anaemia, kidney damage or widespread bone damage. For this reason, plasmacytoma can remain unnoticed for a long time.
Possible symptoms of plasmacytoma include:
- Local pain
- A feeling of pressure or a lump that can be felt
- Bone instability or pathological fractures
- back pain, if the vertebrae are affected
- Neurological symptoms, such as numbness, unsteady walking, tingling or paralysis
- General fatigue or reduced performance
Typical warning signs also depend on the exact location of the plasmacytoma. Still, certain symptoms should be checked carefully. These include lasting local bone pain, unexplained swelling, a sudden fracture without major trauma or neurological problems.
Plasmacytoma diagnosis
The aim of diagnosis is to confirm the local plasma cell growth. Doctors also need to check whether the disease is truly solitary. They must rule out multiple myeloma. This distinction is especially important. It affects treatment and prognosis. Diagnosis often starts because of bone pain, a palpable mass or neurological symptoms. These symptoms can vary depending on the tumour location.
Imaging is an important first step. If a solitary plasmacytoma of bone is suspected, MRI, CT or PET CT are often used. These tests help assess the exact size and spread of the lesion. They also help rule out further lesions. In extramedullary plasmacytoma, imaging can show the exact location and nearby soft tissue structures.
A tissue sample is especially important for confirming the diagnosis. Only a biopsy with later histological examination can clearly show whether plasmacytoma is present. Under the microscope, doctors check whether there is a clonal increase in plasma cells. Immunohistochemical tests are often added. These help define the cells more precisely.
Because plasmacytoma is closely related to multiple myeloma, a full blood test and urinalysis are also used. Common tests include blood count, kidney values, calcium, inflammatory markers, protein electrophoresis, immunofixation and free light chains in serum. In some cases, free light chains are also measured in urine. A bone marrow examination is also performed. It helps assess the extent of plasma cell involvement in the bone marrow.
Plasmacytoma treatment and prognosis
Plasmacytoma treatment mainly depends on the type of disease. Doctors check whether it is a solitary plasmacytoma of bone or an extramedullary plasmacytoma. They also assess whether the disease is still localised. Radiotherapy is currently the standard treatment in most cases. Plasmacytomas are sensitive to radiation. This often allows good local control. Surgery may also be considered. This is especially true when the tumour is easy to reach. Surgery may also be needed in urgent situations, such as instability, fractures or neurological symptoms. Overall, local treatment is usually the standard approach.
Systemic treatment, such as chemotherapy, is usually not part of standard treatment. It may be used in special risk situations. It may also be considered if the response to treatment is insufficient, if the disease returns or if it has already developed into multiple myeloma.
The prognosis of plasmacytoma is often better than that of multiple myeloma. This is because the disease is localised at first. However, many affected people later develop multiple myeloma. For this reason, close follow-up with imaging and laboratory tests is very important. Factors such as age, larger tumours or certain molecular findings can increase the risk of progression.
Alongside conventional medical treatment, complementary approaches may also be used in plasmacytoma. They can support treatment and strengthen well-being. Hyperthermia is also being studied in connection with plasma cell disorders. Preclinical studies show that myeloma cells are especially sensitive to heat. Heating can limit their ability to divide or lead them into programmed cell death. However, there are currently no direct clinical studies for plasmacytoma compared with multiple myeloma.
Supportive measures are better documented. These include adequate vitamin D and calcium intake, especially when bone-protecting therapies are used. Acupuncture may help relieve pain, nausea, sleep disorders or treatment-related neuropathic symptoms. These approaches do not replace local standard therapy. They may, however, support it in a positive way.
Dr. med. Karsten Ostermann M.A.
In plasmacytoma, both the localized disease and the potential for systemic progression should be considered. An integrative approach can help provide individualized support and promote long-term well-being.
Further information
The information listed contains relevant topics and serves to improve understanding.